Sangya Agarwal
Overview
Explore the profile of Sangya Agarwal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang J, Wellhausen N, Engel N, Landmann J, Hopkins C, Salas-Mckee J, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1136-1146.
PMID: 38869428
Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T...
2.
Agarwal S, Aznar M, Rech A, Good C, Kuramitsu S, Da T, et al.
Immunity
. 2023 Sep;
56(10):2388-2407.e9.
PMID: 37776850
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous success treating B cell malignancies; however, some patients fail to respond due to poor autologous T cell fitness....
3.
Watanabe K, Gomez A, Kuramitsu S, Siurala M, Da T, Agarwal S, et al.
Blood Adv
. 2023 Apr;
7(14):3416-3430.
PMID: 37058474
A challenge when targeting T-cell lymphoma with chimeric antigen receptor (CAR) T-cell therapy is that target antigens are often shared between T cells and tumor cells, resulting in fratricide between...
4.
Kalbasi A, Siurala M, Su L, Tariveranmoshabad M, Picton L, Ravikumar P, et al.
Nature
. 2022 Nov;
612(7938):E10.
PMID: 36380037
No abstract available.
5.
Kalbasi A, Siurala M, Su L, Tariveranmoshabad M, Picton L, Ravikumar P, et al.
Nature
. 2022 Jun;
607(7918):360-365.
PMID: 35676488
Synthetic receptor signalling has the potential to endow adoptively transferred T cells with new functions that overcome major barriers in the treatment of solid tumours, including the need for conditioning...
6.
Good C, Aznar M, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al.
Cell
. 2021 Dec;
184(25):6081-6100.e26.
PMID: 34861191
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the...
7.
Wellhausen N, Agarwal S, Rommel P, Gill S, June C
Curr Opin Immunol
. 2021 Nov;
74:76-84.
PMID: 34798542
T cells engineered to express transgenes such as chimeric antigen receptors (CAR) or modified T cell receptors (TCR) represent a new pillar of cancer therapy. Use of CRISPR/Cas gene-editing tools...
8.
Agarwal S, Wellhausen N, Levine B, June C
J Vis Exp
. 2021 Mar;
(169).
PMID: 33779622
Adoptive cell therapies using chimeric antigen receptor T cells (CAR-T cells) have demonstrated remarkable clinical efficacy in patients with hematological malignancies and are currently being investigated for various solid tumors....
9.
Roy N, Kim S, Buffone Jr A, Blumenthal D, Huang B, Agarwal S, et al.
J Cell Sci
. 2020 Sep;
133(17).
PMID: 32907931
T cell entry into inflamed tissue requires firm adhesion, cell spreading, and migration along and through the endothelial wall. These events require the T cell integrins LFA-1 and VLA-4 and...
10.
Agarwal S, June C
Cancer Discov
. 2020 Apr;
10(6):775-778.
PMID: 32303509
Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with COVID-19 by repurposing existing drugs previously developed...